<HashMap><database>biostudies-literature</database><scores/><additional><submitter>He M</submitter><funding>Tianjin Science and Technology Program</funding><funding>Natural Science Foundation of Tianjin City</funding><funding>Ministry of Science and Technology of the People&amp;apos;s Republic of China</funding><funding>National Natural Science Foundation of China</funding><pagination>806837</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8895481</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13</volume><pubmed_abstract>Several approaches to expand human hematopoietic stem cells (hHSCs) clinically along with retainable capability of multipotential differentiation have been reported, but only a few have advanced to evaluation in clinical trials, which limits the application of HSC-based therapy. Here we show a phthalide derivative, Levistilide A (LA), can serve as a promising molecule to expand functional human umbilical cord blood (UCB) HSCs &lt;i>ex vivo&lt;/i>. An in-house screen identified LA out of nine natural products as an outstanding candidate for hHSCs expansion. Additionally, our data indicated that LA treatment not only increased the numbers of phenotype-defined HSCs, but also enhanced their colony formation ability. Xenotransplantation assays showed that LA treatment could maintain unaffected engraf</pubmed_abstract><journal>Frontiers in pharmacology</journal><pubmed_title>Levistilide A Promotes Expansion of Human Umbilical Cord Blood Hematopoietic Stem Cells by Enhancing Antioxidant Activity.</pubmed_title><pmcid>PMC8895481</pmcid><funding_grant_id>92068204 81870083 81970105 81872764 81903456</funding_grant_id><funding_grant_id>20JCQNJC02080</funding_grant_id><funding_grant_id>18ZXXYSY00010</funding_grant_id><funding_grant_id>2017YFA0104900 2016YFA0100600</funding_grant_id><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Yang M</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>He M</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Ding Y</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Xu S</pubmed_authors><pubmed_authors>Liu G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Levistilide A Promotes Expansion of Human Umbilical Cord Blood Hematopoietic Stem Cells by Enhancing Antioxidant Activity.</name><description>Several approaches to expand human hematopoietic stem cells (hHSCs) clinically along with retainable capability of multipotential differentiation have been reported, but only a few have advanced to evaluation in clinical trials, which limits the application of HSC-based therapy. Here we show a phthalide derivative, Levistilide A (LA), can serve as a promising molecule to expand functional human umbilical cord blood (UCB) HSCs &lt;i>ex vivo&lt;/i>. An in-house screen identified LA out of nine natural products as an outstanding candidate for hHSCs expansion. Additionally, our data indicated that LA treatment not only increased the numbers of phenotype-defined HSCs, but also enhanced their colony formation ability. Xenotransplantation assays showed that LA treatment could maintain unaffected engraf</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T08:57:28.652Z</modification><creation>2025-04-04T08:57:28.652Z</creation></dates><accession>S-EPMC8895481</accession><cross_references><pubmed>35250558</pubmed><doi>10.3389/fphar.2022.806837</doi></cross_references></HashMap>